The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 24th 2024
Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.
What Happens to Patients With Diabetes When Semaglutide Dosing Is Disrupted? Dr Ian Neeland Explains
January 11th 2024Possible long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events.
Watch
Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups
January 10th 2024Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
Read More
What We’re Reading: Doctor Payment Cuts; Menopause Drug; Student Mental Health Support
January 10th 2024Congress is being urged to reverse a cut to physicians’ Medicare payments; Bayer announced encouraging results on Monday of 2 phase 3 trials for its nonhormonal drug candidate meant to treat hot flashes; more students are turning to online mental health support rather than school counselors.
Read More
Dr Ian Neeland Explains Why Semaglutide Shortage Impacts Injectable and Not Oral Version
January 10th 2024According to Ian Neeland, MD, there are 2 main reasons for the shortage of injectable semaglutide: the fact that oral semaglutide has not yet been tested for weight loss, and that most practitioners just overlook it as an option.
Watch
What We’re Reading: Mask Mandates Return; Sugary Drink Sales Decline; WIC Program Problems
January 8th 2024COVID-19 subvariant JN.1 accounts for about 62% of US cases, resulting in mask mandates being reinstated in cities across the United States; sugary drink sales fell dramatically across 5 US cities after implementing taxes on them; it is difficult for Special Supplement Nutrition Program for Women and Children (WIC) participants to find approved items.
Read More
Maternal T1D Associated With Risk of Congenital Heart Defects in Offspring
January 5th 2024A Finnish study found maternal type 1 diabetes (T1D) to be associated with a significantly higher risk of any congenital heart defect (CHD) in offspring, and that maternal overweight or obesity was associated with certain CHDs in offspring.
Read More
Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era
January 5th 2024An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
Read More
What We’re Reading: Canadian Drug Imports; Drug-by-Mail Delivery; Hydroxychloroquine-Related Deaths
January 5th 2024The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States; health insurance companies are revamping their technology to encourage more people to get their medications through the mail; nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave.
Read More
Dr Jonathan Silverberg Lists Which Patients With AD Benefit Most From JAK Inhibitors
January 4th 2024Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Watch
What We’re Reading: Rising Hospital Care Costs; New Antibiotic; Disenrolled Medicaid Beneficiaries
January 4th 2024The average direct cost for hospital treatment for patients with COVID-19 in the United States rose by 26% from 2020 to 2022; scientists have developed a new type of antibiotic to treat a deadly bacteria resistant to most current antibiotics; a survey conducted for Utah state officials gave some clues as to why millions of Americans lost Medicaid coverage last year.
Read More
Experts explore the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advances in metastatic breast cancer treatment.
Watch